Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Mallard Acquisition (MACUU)
MingZhu Logistics Holdings (YGMZ)
Good Works Acquisition (GWACU)
Bull Horn Holdings (BHSEU)
Decarbonization Plus Acquistion (DCRBU)
Horizon Acquisition II (HZON.U)
Helix Acquisition (HLXA)
Datto Holding Corp. (MSP)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Foghorn Therapeutics Inc. (FHTX)
Gatos Silver, Inc. (GATO)
Priced IPO
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
Array Technologies, Inc. (ARRY)
MINISO Group Holding Limited (MNSO)
Codiak BioSciences, Inc. (CDAK)
Intrusion Securties Inc. (INTZ)
iHuman Inc. (IH)
Shattuck Labs, Inc. (STTK)
Kronos Bio, Inc. (KRON)
Spruce Biosciences, Inc. (SPRB)
Aziyo Biologics, Inc. (AZYO)
fuboTV Inc. (FUBO)
Presidio Property Trust (SQFT)
Academy Sports and Outdoors, Inc. (ASO)
Immunome Inc. (IMNM)
C4 Therapeutics, Inc. (CCCC)
Oncorus, Inc (ONCR)
More companies

Aziyo Biologics, Inc. (AZYO)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From their proprietary tissue processing platforms, they have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material. Their proprietary products, which they refer to as their Core Products, are designed to address the implantable electronic device/cardiovascular, orthopedic/spinal repair and soft tissue reconstruction markets, which represented a combined $3 billion market opportunity in the United States in 2019. To expand their commercial reach, they have commercial relationships with major medical device companies, such as Boston Scientific and Medtronic, to promote and sell some of their Core Products. They believe their focus on their unique regenerative medicine platforms and their Core Products will ultimately maximize their probability of continued clinical and commercial success and will create a long-term competitive advantage for them.
Industry
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
CEO CFO
Ronald Lloyd Matthew Ferguson
Employees Founded
151 2015

Contacts

Address: 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904

Telephone: (240) 247-1170

Web page: http://www.aziyo.com

IPO information

Expected Date 10/8/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $133.1
Revenues (MM) $23.2
Net Income (Loss) (MM) $-15.6

Voting

What do you think will happen with the AZYO share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 2.9
Shares Revised (MM) 2.9
Expected offer amount (MM) $49.3
Realized offer amount(MM) $49.3
Underwriters
Piper Sandler/ Cowen
CO-Managers
Cantor/ Truist Securities

Sector: Healthcare

Tweets about $AZYO

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats